Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Risk factors for acquisition of SARS-CoV-2 Omicron variant among a prospective cohort of French Healthcare Workers: impact of hybrid immunity.

Scientific reports·2026
Same author

Sequential axitinib and survivin vaccination unlock curative PD-1 immunotherapy in renal carcinoma.

Oncoimmunology·2026
Same author

Importance of the delivery route for the tolerability and efficacy of immunomodulatory agents for lung cancer.

Scientific reports·2026
Same author

The critical role of the endogenous immune compartment after CAR T cell therapy in recurrent GBM.

Cell·2026
Same author

Safety and efficacy of intratumoural anti-CTLA4 with intravenous anti-PD1.

Nature·2026
Same author

INST'AJA: a co-designed Instagram campaign to promote sexual health education and behaviors in adolescent and young adult cancer survivors.

The journal of sexual medicine·2026

Related Experiment Video

Updated: May 10, 2026

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care
12:55

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Published on: February 16, 2015

Trial Watch: Adoptive cell transfer for anticancer immunotherapy.

Erika Vacchelli1, Alexander Eggermont, Wolf Hervé Fridman

  • 1Institut Gustave Roussy; Villejuif, France ; Université Paris-Sud/Paris XI; Le Kremlin-Bicêtre; Paris France ; INSERM, U848; Villejuif, France.

Oncoimmunology
|June 14, 2013
PubMed
Summary
This summary is machine-generated.

Adoptive cell transfer (ACT) is a key cancer immunotherapy. Recent advancements focus on enhancing T-cell persistence and rejuvenating exhausted cells for improved clinical outcomes in cancer treatment.

Keywords:
FOXP3+ regulatory T cellsT-cell receptorchimeric antigen receptorcyclophosphamidelymphodepletiontumor-infiltrating lymphocytes

More Related Videos

Experimental Metastasis and CTL Adoptive Transfer Immunotherapy Mouse Model
08:06

Experimental Metastasis and CTL Adoptive Transfer Immunotherapy Mouse Model

Published on: November 26, 2010

Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer
07:55

Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer

Published on: January 17, 2025

Related Experiment Videos

Last Updated: May 10, 2026

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care
12:55

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Published on: February 16, 2015

Experimental Metastasis and CTL Adoptive Transfer Immunotherapy Mouse Model
08:06

Experimental Metastasis and CTL Adoptive Transfer Immunotherapy Mouse Model

Published on: November 26, 2010

Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer
07:55

Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer

Published on: January 17, 2025

Area of Science:

  • Immunology
  • Oncology
  • Cellular Therapy

Background:

  • Adoptive cell transfer (ACT) is a significant immunotherapy for malignant diseases.
  • It involves ex vivo expansion and reintroduction of autologous lymphocytes with antitumor activity.
  • ACT differs from cellular vaccines and allogeneic transplantation.

Purpose of the Study:

  • To summarize recent developments in ACT research and clinical trials.
  • To cover high-impact studies and newly initiated clinical trials in the last 13 months.
  • To assess the antineoplastic profile of ACT.

Main Methods:

  • Isolation of autologous lymphocytes (tumor-infiltrating or engineered circulating cells).
  • Ex vivo expansion, activation, and potential genetic modification of lymphocytes.
  • In vitro rejuvenation of exhausted T lymphocytes using cytokine cocktails.
  • Administration in conjunction with lymphodepleting regimens and immunostimulatory agents.

Main Results:

  • Recent studies highlight strategies to enhance lymphocyte persistence and antitumor responses.
  • Genetic modification of lymphocytes can improve in vivo efficacy and reduce side effects.
  • T-cell rejuvenation in vitro shows promise for improving ACT clinical success.
  • Ongoing clinical trials are evaluating the antineoplastic effects of ACT.

Conclusions:

  • ACT remains a prominent and evolving form of cancer immunotherapy.
  • Advances in cell engineering and rejuvenation strategies are enhancing its potential.
  • Continuous research and clinical trials are crucial for optimizing ACT efficacy.